Fundz

Entrada Therapeutics, Inc. reported raising $116 Million in an initial SEC Form D filing, from an offering of $116 Million

PUBLIC · TRDAApr 13, 2021

Amount Raised

$116 Million

$116 Million sold, per SEC Form D (first sale Apr 13, 2021)

Round Type

Venture

BostonHealthcareBiotechnology Research

Quick answer

Entrada Therapeutics, Inc. raised $116 Million in a funding round, dated April 13, 2021. Entrada Therapeutics, Inc. is based in Boston, Massachusetts, United States.

How much did Entrada Therapeutics, Inc. raise?
Entrada Therapeutics, Inc. raised $116 Million in a funding round on April 13, 2021.
What does Entrada Therapeutics, Inc. do?
Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics.
Where is Entrada Therapeutics, Inc. based and how big is it?
Entrada Therapeutics, Inc. is based in Boston, Massachusetts, United States. Fundz records about 51 employees.
Who are the decision-makers at Entrada Therapeutics, Inc?
Fundz holds 1 contact at Entrada Therapeutics, Inc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Biotechnology Research around the same time

Companies in the same sectors as Entrada Therapeutics, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Spesana Inc. raised $3M (Seed) on May 26, 2021.
  • Definitive Biotechnologies raised $1.4M (Seed) on April 22, 2021.
  • Heru, Inc. raised $29M on May 28, 2021.
  • Climb Bio, Inc. raised $60M on May 28, 2021.
  • Restor3D raised $13M on May 28, 2021.
  • Medico CX, Inc. raised $505K (Seed) on May 28, 2021.

Who to call at Entrada Therapeutics, Inc., and when

A new round usually means Entrada Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Entrada Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Entrada Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Entrada Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Entrada Therapeutics, Inc.

Location

6 TIDE STREET

Boston, Massachusetts, United States

About

Headquartered in Boston’s Seaport community, Entrada Therapeutics is a growing biopharmaceutical company innovating to transform the treatment of devastating diseases through intracellular therapeutics. We’re establishing a new class of medicines, Endosomal Escape Vehicles (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. Our EEV™ therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through our proprietary, highly versatile, and modular EEV™ Platform, we are building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. Our lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as our partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1). For more information about Entrada, please visit www.entradatx.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Entrada Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts6 people are listed at Entrada Therapeutics, Inc.. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Entrada Therapeutics, Inc.'s next move

See what Strategic adds

Entrada Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.